Last reviewed · How we verify
Ticagrelor and Aspirin
Ticagrelor is a P2Y12 receptor antagonist that inhibits platelet activation and aggregation, while aspirin is a non-selective COX inhibitor that reduces platelet aggregation.
Ticagrelor is a P2Y12 receptor antagonist that inhibits platelet activation and aggregation, while aspirin is a non-selective COX inhibitor that reduces platelet aggregation. Used for Acute coronary syndrome, Myocardial infarction, Stroke prevention in atrial fibrillation.
At a glance
| Generic name | Ticagrelor and Aspirin |
|---|---|
| Sponsor | Beijing Tiantan Hospital |
| Drug class | P2Y12 receptor antagonist and non-selective COX inhibitor |
| Target | P2Y12 receptor and COX-1 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Ticagrelor works by selectively and reversibly binding to the P2Y12 receptor on platelet surfaces, preventing adenosine diphosphate (ADP) from binding and activating the receptor. Aspirin, on the other hand, irreversibly inhibits the COX-1 enzyme, which is responsible for producing thromboxane A2, a potent platelet activator. By inhibiting these pathways, both drugs reduce platelet aggregation and the risk of thrombotic events.
Approved indications
- Acute coronary syndrome
- Myocardial infarction
- Stroke prevention in atrial fibrillation
Common side effects
- Bleeding
- Dyspnea
- Headache
Key clinical trials
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome (PHASE4)
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
- Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone (PHASE3)
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation (PHASE4)
- Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |